- company,
through the
formation of
Elusys Therapeutics to
raise several million dollars. Jeff Wolf, the
founding CEO
Elusys and
Managing Partner of Seed-One...
-
anthracis spores (etiologic
agent of anthrax). The
medication was
developed by
Elusys Therapeutics, Inc.
Obiltoxaximab is
indicated in
combination with appropriate...
-
squamous non-small cell lung
carcinoma 125527 Link
obiltoxaximab Anthem Elusys Therapeutics 3/18/2016
intravenous chimeric Protective antigen of the Anthrax...
- Pharmaceuticals, Avertis, Xoma Corporation,
Dynavax Technologies Incorporation,
Elusys Therapeutics,
DynPort Vaccine Company LLC,
Bavarian Nordic and Nanotherapeutics...
-
antitoxins Anthrasil of
Cangene (March 2015 FDA approval) and
Anthim of
Elusys Therapeutics (March 2016 FDA approval).
Anthrax vaccines whose development...
-
antibody that can
neutralize the
anthrax toxin,
which was
developed by
Elusys Therapeutics as
Anthim (Obiltoxaximab). The drug was
approved by the Food...
-
International BioCryst iBio / CC-Pharming (former)
Chimerix Coherus CUBRC, Inc.
Elusys Therapeutics, Inc.
Emerald Bioscience (former)
Emergent BioSolutions GSK...
- and
medical device companies)
Johnson &
Johnson Celgene PTC
Therapeutics Elusys Therapeutics Vicus Genmab Merck Sanofi-Aventis Bristol-Myers
Squibb Middle****...
-
directorships since retiring from BMS is extensive, the
following is a selection:
Elusys Therapeutics: Chairman, 2000–2007; Director, 2007–2009
ImClone Systems:...
